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CDC recommends against the use of amantadine and rimantidine for treatment of 
seasonal influenza 
On the basis of recently available antiviral testing results, the Centers for Disease Control 
and Prevention (CDC) recommends that neither amantadine nor rimantadine be used for 
the treatment or chemoprophylaxis of influenza A infections in the U.S. for the remainder 
of the 2005-06 influenza season. During this period, oseltamivir or zanamivir should be 
prescribed if an antiviral medication is indicated for the treatment of influenza. 
Oseltamivir should be prescribed for chemoprophylaxis of influenza. 
From Oct. 1, 2005 to Jan. 14, 2006, a total of 123 influenza A viruses collected from 23 
states were tested at CDC for adamantane resistance. Among the 120 influenza A (H3N2) 
viruses tested, 109 (91 percent) demonstrated the S31N substitution in the M2 protein 
that confers resistance to amantadine and rimantadine. These high levels of resistance 
necessitate the interim change in recommendations for the use of these drugs. Testing of 
influenza isolates for resistance to antivirals will continue throughout the 2005-06 
influenza season. Recommendations will be updated as needed. 
Recommendations for the use of oseltamivir and zanamivir have not changed. The Food 
and Drug Administration (FDA) recently extended chemoprophylaxis approval of 
oseltamivir to include children aged 1-12 years; previously, chemoprophylaxis approval 
had been limited to children 13 years old and older.  
When administered for treatment within 48 hours of illness onset, neuraminidase 
inhibitors can reduce the duration of uncomplicated influenza A and B illness by 
approximately one day. Persons at high risk for serious complications from influenza can 
benefit most from neuraminidase inhibitors. CDC recommends that neuraminidase 
inhibitors be used as treatment for any person experiencing a potentially life-threatening 
influenza-related illness and for persons at high risk for serious complications from 
influenza. CDC recommends that oseltamivir be used as chemoprophylaxis for 1) persons 
who live or work in institutions caring for persons at high risk for serious complications 
from influenza infection in the event of an institutional outbreak, and 2) persons at high 
risk for serious influenza complications if they are likely to be exposed to others infected 
with influenza. The FDA-approved indications for the use of neuraminidase inhibitors are 
available at www.cdc.gov/flu/professionals/treatment.  
To view the CDC dispatch, go to www.cdc.gov/flu/han011406.htm .  
Influenza update 
Seasonal influenza: Iowa and the United States 
Twenty-four Iowa counties have had recent flu activity. Scott County has had both influenza A 
and B activity. Only one case of influenza B has been confirmed this season. All confirmed strains 
still match the vaccine strain. Nearly 50 cases of influenza have been confirmed by the University 
Hygienic Lab (UHL) this season.  
There was a slight decrease in influenza-like illness (ILI ) activity for all Iowa Influenza 
Surveillance Network (IISN) reporting groups. However, cases of flu continue to be confirmed in 
new counties at similar levels to the previous two weeks. This indicates that Iowa cases have not 
yet peaked, and that levels of ILI could increase at any time.   
Several Western states are still reporting widespread activity. For more information on influenza, 
please visit our Web site at www.idph.state.ia.us/adper/flu.asp.  
Avian influenza 
Cases continue to be reported by Turkish health officials, though not all have been confirmed by 
the World Health Organization (WHO). Turkey reports 21 cases and four deaths. Of those, WHO 
has confirmed four cases and two deaths. Activity remains the same in five countries, Turkey, 
China, Thailand, Indonesia and Vietnam.  
The public health impact of viral encephalitis/meningitis 
In last week’s Epi Update, we discussed the public health response to bacterial meningitis. 
Viruses can also cause meningitis, an inflammation of the surrounding membranes of the brain 
and spinal cord, and is relatively common. Many different viruses can cause meningitis, but the 
coxsackievirus and echovirus - both enteroviruses - are responsible for the majority of identified 
viral meningitis cases in the U.S. Most viruses that cause meningitis are transmitted primarily 
person to person. However, because the disease is normally not severe and since there is no 
recommended prophylaxis for contacts, a public health response is not indicated for individual 
cases. 
Arboviral encephalitis, inflammation of the brain, includes diseases spread by mosquitoes. 
Individual case reports and public health follow up is required. Some of the diseases in this 
category are Saint Louis Encephalitis, LaCrosse Encephalitis, Western Equine Encephalitis, 
Eastern Equine Encephalitis and Venezuelan Equine Encephalitis. West Nile Virus may cause 
either meningitis or encephalitis and both require a public health response.  
Meeting announcements 
UHL will present the Diagnostic Microbiology for Epidemiologists course over the Iowa 
Communications Network (ICN) again this year. This course is designed to introduce public 
health professionals to microbiology laboratory testing including culture, antigen detection, 
serology, and molecular amplification laboratory techniques for bacteria, viruses, parasites and 
fungi. It is offered through the University of Iowa’s College of Public Health. The course number is 
173:155. 
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